BioMarin Pharmaceuticals
BMRN
460 hedge funds and large institutions have $17.6B invested in BioMarin Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 173 increasing their positions, 156 reducing their positions, and 29 closing their positions.
55% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 29
11% more repeat investments, than reductions
Existing positions increased: 173 | Existing positions reduced: 156
2% more funds holding
Funds holding: 449 → 460 (+11)
8% more call options, than puts
Call options by funds: $131M | Put options by funds: $122M
2% more capital invested
Capital invested by funds: $17.2B → $17.6B (+$354M)
1.52% less ownership
Funds ownership: 103.52% → 102% (-1.5%)
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$210M |
| 2 |
BlackRock
New York
|
+$100M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
+$86.8M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$62.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$62.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
-$204M |
| 2 |
Temasek Holdings
Singapore
|
-$110M |
| 3 |
SIG
Senator Investment Group
New York
|
-$94.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$80.8M |
| 5 |
Jennison Associates
New York
|
-$74.3M |
BMRN Hedge Fund Activity: Q3 2018 in Review
460 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2018, worth a combined $17.6B — up 2.1% from $17.2B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new BMRN positions and 29 closed out — a net gain of 16 holders — while 173 added to existing stakes and 156 trimmed.
The largest buyer was Capital International Investors, opening a new position worth an estimated $210M. The largest seller was Capital Research Global Investors, cutting an estimated $204M.
- 460 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2018, up from 449 in Q2 2018.
- Funds reported $17.6B of BioMarin Pharmaceuticals stock for Q3 2018, up 2.1% quarter-over-quarter.
- 45 funds opened new BioMarin Pharmaceuticals positions in Q3 2018 and 29 closed out, a net change of +16 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2018 was Capital International Investors, an estimated $210M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2018 was Capital Research Global Investors, an estimated $204M sold.
Based on aggregated 13F filings for Q3 2018.